Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 2000 Jun 27;162(13):1843–1848.

Raves: a review of the culture, the drugs and the prevention of harm

E Weir 1
PMCID: PMC1231377  PMID: 10906922

Abstract

Raves are all-night dance parties attended by large numbers of youth, sometimes in excess of 20,000. The rave scene, which is international in scope, is distinguished by clandestine venues, hypnotic electronic music and the liberal use of drugs such as ecstasy (3,4-methylenedioxymethamphetamine), GHB (gamma-hydroxybutyrate) and ketamine. Several rave-related deaths in Canada in 1999 alerted health authorities, parents and police to the health risks of rave attendance. Family physicians, emergency physicians and pediatricians should have some understanding of raves, the drugs and the health risks so they can effectively counsel and treat patients. The rave culture in Canada and the drugs commonly used at raves are reviewed, and strategies and initiatives for harm reduction are discussed.

Full Text

The Full Text of this article is available as a PDF (434.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adlaf E. M., Smart R. G. Party subculture or dens of doom? An epidemiological study of rave attendance and drug use patterns among adolescent students. J Psychoactive Drugs. 1997 Apr-Jun;29(2):193–198. doi: 10.1080/02791072.1997.10400187. [DOI] [PubMed] [Google Scholar]
  2. Box S. A., Prescott L. F., Freestone S. Hyponatraemia at a rave. Postgrad Med J. 1997 Jan;73(855):53–54. doi: 10.1136/pgmj.73.855.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brown E. R., Jarvie D. R., Simpson D. Use of drugs at 'raves'. Scott Med J. 1995 Dec;40(6):168–171. doi: 10.1177/003693309504000604. [DOI] [PubMed] [Google Scholar]
  4. Buxton J., Craig C., Daly P., Bigham M., Bell A., Fyfe M. An outbreak of mumps among young adults in Vancouver, British Columbia, associated with 'rave' parties. Can J Public Health. 1999 May-Jun;90(3):160–163. doi: 10.1007/BF03404498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Coore J. R. A fatal trip with ecstasy: a case of 3,4-methylenedioxymethamphetamine/3,4- methylenedioxyamphetamine toxicity. J R Soc Med. 1996 Jan;89(1):51P–52P. doi: 10.1177/014107689608900115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Crespi D., Mennini T., Gobbi M. Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. Br J Pharmacol. 1997 Aug;121(8):1735–1743. doi: 10.1038/sj.bjp.0701325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dalgarno P. J., Shewan D. Illicit use of ketamine in Scotland. J Psychoactive Drugs. 1996 Apr-Jun;28(2):191–199. doi: 10.1080/02791072.1996.10524391. [DOI] [PubMed] [Google Scholar]
  8. Fidler H., Dhillon A., Gertner D., Burroughs A. Chronic ecstasy (3,4-methylenedioxymetamphetamine) abuse: a recurrent and unpredictable cause of severe acute hepatitis. J Hepatol. 1996 Oct;25(4):563–566. doi: 10.1016/s0168-8278(96)80217-0. [DOI] [PubMed] [Google Scholar]
  9. Forsyth A. J., Barnard M., McKeganey N. P. Musical preference as an indicator of adolescent drug use. Addiction. 1997 Oct;92(10):1317–1325. [PubMed] [Google Scholar]
  10. Forsyth A. J. Places and patterns of drug use in the Scottish dance scene. Addiction. 1996 Apr;91(4):511–521. doi: 10.1046/j.1360-0443.1996.9145116.x. [DOI] [PubMed] [Google Scholar]
  11. Goldstein J. C., Waterhouse N. J., Juin P., Evan G. I., Green D. R. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol. 2000 Mar;2(3):156–162. doi: 10.1038/35004029. [DOI] [PubMed] [Google Scholar]
  12. Green A. R., Cross A. J., Goodwin G. M. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology (Berl) 1995 Jun;119(3):247–260. doi: 10.1007/BF02246288. [DOI] [PubMed] [Google Scholar]
  13. Hegadoren K. M., Baker G. B., Bourin M. 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev. 1999 Mar;23(4):539–553. doi: 10.1016/s0149-7634(98)00046-3. [DOI] [PubMed] [Google Scholar]
  14. Jones A. L., Volans G. Management of self poisoning. BMJ. 1999 Nov 27;319(7222):1414–1417. doi: 10.1136/bmj.319.7222.1414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kohrs R., Durieux M. E. Ketamine: teaching an old drug new tricks. Anesth Analg. 1998 Nov;87(5):1186–1193. doi: 10.1097/00000539-199811000-00039. [DOI] [PubMed] [Google Scholar]
  16. Li J., Stokes S. A., Woeckener A. A tale of novel intoxication: a review of the effects of gamma-hydroxybutyric acid with recommendations for management. Ann Emerg Med. 1998 Jun;31(6):729–736. [PubMed] [Google Scholar]
  17. MacConnachie A. M. Ecstasy poisoning. Intensive Crit Care Nurs. 1997 Dec;13(6):365–366. doi: 10.1016/s0964-3397(97)81146-9. [DOI] [PubMed] [Google Scholar]
  18. Milroy C. M. Ten years of 'ecstasy'. J R Soc Med. 1999 Feb;92(2):68–72. doi: 10.1177/014107689909200206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Moore K. A., Kilbane E. M., Jones R., Kunsman G. W., Levine B., Smith M. Tissue distribution of ketamine in a mixed drug fatality. J Forensic Sci. 1997 Nov;42(6):1183–1185. [PubMed] [Google Scholar]
  20. Peña B. M., Krauss B. Adverse events of procedural sedation and analgesia in a pediatric emergency department. Ann Emerg Med. 1999 Oct;34(4 Pt 1):483–491. doi: 10.1016/s0196-0644(99)80050-x. [DOI] [PubMed] [Google Scholar]
  21. Rochester J. A., Kirchner J. T. Ecstasy (3,4-methylenedioxymethamphetamine): history, neurochemistry, and toxicology. J Am Board Fam Pract. 1999 Mar-Apr;12(2):137–142. doi: 10.3122/jabfm.12.2.137. [DOI] [PubMed] [Google Scholar]
  22. Rudnick G., Wall S. C. The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1817–1821. doi: 10.1073/pnas.89.5.1817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Salt P. Public health. Rave review. Nurs Times. 1993 Dec 15;89(50):36–38. [PubMed] [Google Scholar]
  24. Schwartz R. H., Miller N. S. MDMA (ecstasy) and the rave: a review. Pediatrics. 1997 Oct;100(4):705–708. doi: 10.1542/peds.100.4.705. [DOI] [PubMed] [Google Scholar]
  25. Seymour H. R., Gilman D., Quin J. D. Severe ketoacidosis complicated by 'ecstasy' ingestion and prolonged exercise. Diabet Med. 1996 Oct;13(10):908–909. doi: 10.1002/(SICI)1096-9136(199610)13:10<908::AID-DIA249>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  26. Sherlock K., Wolff K., Hay A. W., Conner M. Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. J Accid Emerg Med. 1999 May;16(3):194–197. doi: 10.1136/emj.16.3.194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sultana S. R., Byrne D. J. 'Raver's' haematuria. J R Coll Surg Edinb. 1996 Dec;41(6):419–420. [PubMed] [Google Scholar]
  28. Wollina U., Kammler H. J., Hesselbarth N., Mock B., Bosseckert H. Ecstasy pimples - a new facial dermatosis. Dermatology. 1998;197(2):171–173. doi: 10.1159/000017992. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES